Terms: = Breast cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
42 results:
1. Profiling regulatory T lymphocytes within the tumor microenvironment of breast cancer via radiomics.
Jiang W; Wu R; Yang T; Yu S; Xing W
Cancer Med; 2023 Dec; 12(24):21861-21872. PubMed ID: 38083903
[TBL] [Abstract] [Full Text] [Related]
2. CHSY1 promotes CD8
Sun G; Zhao S; Fan Z; Wang Y; Liu H; Cao H; Sun G; Huang T; Cai H; Pan H; Rong D; Gao Y; Tang W
J Exp Clin Cancer Res; 2023 Sep; 42(1):248. PubMed ID: 37749638
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy in Early-Stage Triple-Negative breast cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract] [Full Text] [Related]
4. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies.
Guo X; Chen S; Wang X; Liu X
Front Immunol; 2023; 14():1138483. PubMed ID: 37081866
[TBL] [Abstract] [Full Text] [Related]
5. Metastasis of breast cancer to bones alters the tumor immune microenvironment.
Chao X; Zhang Y; Zheng C; Huang Q; Lu J; Pulver EM; Houthuijzen J; Hutten S; Luo R; He J; Sun P
Eur J Med Res; 2023 Mar; 28(1):119. PubMed ID: 36915210
[TBL] [Abstract] [Full Text] [Related]
6. Case report and literature review on a large MBC with ulceration.
Luo QQ; Luo NN
Medicine (Baltimore); 2023 Mar; 102(9):e33131. PubMed ID: 36862895
[TBL] [Abstract] [Full Text] [Related]
7. Rational Design of Polymethine Dyes with NIR-II Emission and High Photothermal Conversion Efficiency for Multimodal-Imaging-Guided Photo-Immunotherapy.
Ran XY; Chen P; Liu YZ; Shi L; Chen X; Liu YH; Zhang H; Zhang LN; Li K; Yu XQ
Adv Mater; 2023 Mar; 35(12):e2210179. PubMed ID: 36630669
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Camrelizumab associated with central retinal vein occlusion.
Zhan Y; Zhao W; Ni K; Liu Z; Su Y; Li X; Zhang H; Zhang C
Front Immunol; 2022; 13():1025125. PubMed ID: 36505454
[TBL] [Abstract] [Full Text] [Related]
9. High co-expression of immune checkpoint receptors pd-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract] [Full Text] [Related]
10. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung cancer in a Patient with a History of breast cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract] [Full Text] [Related]
11. Lichen-planus-pemphigoides-like reaction to pd-1 checkpoint blockade.
Wat M; Mollanazar NK; Ellebrecht CT; Forrestel A; Elenitsas R; Chu EY
J Cutan Pathol; 2022 Nov; 49(11):978-987. PubMed ID: 36054729
[TBL] [Abstract] [Full Text] [Related]
12. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
[TBL] [Abstract] [Full Text] [Related]
13. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.
Amir Taghavi B; Alizadeh N; Saeedi H; Karim Ahangar N; Derakhshani A; Hajiasgharzadeh K; Silvestris N; Baradaran B; Brunetti O
Molecules; 2022 May; 27(11):. PubMed ID: 35684481
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Features of Multiple Primary Malignant Tumors: A Retrospective Clinical Analysis of 213 Chinese Patients at Two Centers.
Wang Y; Jiao F; Yao J; Zhou X; Zhang X; Wang L
Discov Med; 2021; 32(166):65-78. PubMed ID: 35219347
[TBL] [Abstract] [Full Text] [Related]
15. Recent Advances of Nanotechnology in the diagnosis and Therapy of Triple- Negative breast cancer (TNBC).
Kanugo A; Gautam RK; Kamal MA
Curr Pharm Biotechnol; 2022; 23(13):1581-1595. PubMed ID: 34967294
[TBL] [Abstract] [Full Text] [Related]
16. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
[TBL] [Abstract] [Full Text] [Related]
17. A Review of Therapeutic Antibodies in breast cancer.
Eini M; Zainodini N; Montazeri H; Mirzabeigi P; Tarighi P
J Pharm Pharm Sci; 2021; 24():363-380. PubMed ID: 34310275
[TBL] [Abstract] [Full Text] [Related]
18. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au L; Fendler A; Shepherd STC; Rzeniewicz K; Cerrone M; Byrne F; Carlyle E; Edmonds K; Del Rosario L; Shon J; Haynes WA; Ward B; Shum B; Gordon W; Gerard CL; Xie W; Joharatnam-Hogan N; Young K; Pickering L; Furness AJS; Larkin J; Harvey R; Kassiotis G; Gandhi S; ; Swanton C; Fribbens C; Wilkinson KA; Wilkinson RJ; Lau DK; Banerjee S; Starling N; Chau I; ; Turajlic S
Nat Med; 2021 Aug; 27(8):1362-1366. PubMed ID: 34040262
[TBL] [Abstract] [Full Text] [Related]
19. Immunotherapy: New insights in breast cancer treatment.
Alshehri B
Hum Antibodies; 2021; 29(3):193-202. PubMed ID: 33998534
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative breast cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract] [Full Text] [Related]
[Next]
